As filed with the Securities and Exchange Commission
on August 9, 2023
File
No. 333-
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM S-8
REGISTRATION
STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NUVECTIS
PHARMA, INC.
(Exact
name of registrant as specified in its charter)
Delaware |
|
86-2405608 |
(State
or other jurisdiction of incorporation or
organization) |
|
(I.R.S.
Employer Identification No.) |
1
Bridge Plaza Suite 275
Fort
Lee, NJ 07024
(Address,
including Zip Code, of Principal Executive Offices)
Amended
and Restated Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021)
(Full
title of the plan)
Ron
Bentsur
Chairman
and Chief Executive Officer
Nuvectis
Pharma, Inc.
Bridge Plaza Suite 275
Fort
Lee, NJ 07024
(201)
614-3151
(Name,
address and telephone number of agent for
service) |
Matthew
W. Mamak, Esq.
Alston &
Bird LLP
90
Park Avenue, 14th Floor
New York, New York 10016
(212)
210-1256
|
Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,”
“smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:
Large accelerated filer |
¨ |
Accelerated filer |
¨ |
Non-accelerated filer |
x |
Smaller reporting company |
x |
|
|
Emerging growth company |
x |
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨
EXPLANATORY
NOTE
Nuvectis
Pharma, Inc. (the “Company”) has filed this Registration Statement on Form S-8 (this “Registration Statement”)
with the Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as amended (the “Securities
Act”), to register (i) 1,000,000 shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”),
that may be issued under the Nuvectis Pharma, Inc. Amended and Restated Global Incentive Plan (2021) (the “Plan”); and
(ii) such additional shares that may become issuable in accordance with the adjustment and anti-dilution provisions of the Plan.
PART I
INFORMATION
REQUIRED IN THE SECTION 10(a) PROSPECTUS
(a) The
documents constituting Part I of this registration statement on Form S-8 (this “Registration Statement”) will be
delivered to participants in the Plan as specified by Rule 428(b)(1) under the Securities Act. These documents and the documents
incorporated by reference in this Registration Statement pursuant to Item 3 of Part II of this form, taken together, constitute
a prospectus that meets the requirements of Section 10(a) of the Securities Act.
(b) Upon
written or oral request, the Company will provide, without charge, the documents incorporated by reference in Item 3 of Part II
of this Registration Statement. The documents are incorporated by reference in the Section 10(a) prospectus. The Company will
also provide, without charge, upon written or oral request, other documents required to be delivered to participants pursuant to Rule 428(b).
Requests for the above-mentioned information should be directed to our corporate headquarters at the following address: 1 Bridge Plaza,
Suite 275, Fort Lee, NJ 07024, Attn: Ron Bentsur, or by calling (201) 614-3151.
PART II
INFORMATION
REQUIRED IN THE REGISTRATION STATEMENT
Item 3. | Incorporation
of Documents by Reference. |
The
following documents, filed by the Company with the Securities and Exchange Commission (the “Commission”) pursuant to the
Securities Exchange Act of 1934, as amended (the “Exchange Act”), are incorporated herein by reference and deemed to be a
part hereof (excluding any portions of such documents that are deemed to be “furnished” but not “filed” for purposes
of the Exchange Act):
| (a) | The
Company’s Annual Report on Form 10-K for the fiscal year ended December 31,
2022, as amended, filed on March 8, 2023 and amended on March 27, 2023; |
| (b) | The Company’s Quarterly
Reports on Form 10-Q for the quarters ended March 31, 2023, filed on May 10, 2023 and June 30, 2023, filed on August 9, 2023; |
| (d) | The
description of the Company’s Common Stock contained in Exhibit 4.6 to our
Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and any
amendment or report filed with the Commission for the purpose of updating such description; |
| (e) | All
reports filed by the Company pursuant to Section 13(a) or 15(d) of the Securities
Exchange Act of 1934, as amended (the “Exchange Act”) since December 31,
2021 (excluding any portions of such documents that are deemed to be “furnished”
but not “filed” for purposes of the Exchange Act); and |
| (f) | All
other documents subsequently filed by the Company pursuant to Section 13(a), 13(c),
14 and 15(d) of the Exchange Act prior to the filing of a post-effective amendment to
this Registration Statement that indicates that all securities offered have been sold or
that deregisters all securities that remain unsold. |
Any
statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded
for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document
which also is incorporated or deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement
so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.
Item
4. |
Description
of Securities. |
Not
applicable.
Item 5. |
Interests of Named Experts and Counsel. |
Not
applicable.
Item 6. | Indemnification
of Directors and Officers. |
Section 102
of the Delaware General Corporation Law permits a corporation to eliminate the personal liability of its officers or directors to the
company or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his
or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a law, authorized the payment
of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper benefit. Our certificate
of incorporation provides that no officer or director shall be personally liable to us or our stockholders for monetary damages for any
breach of fiduciary duty as an officer or director, notwithstanding any provision of law imposing such liability, except to the extent
that the Delaware General Corporation Law prohibits the elimination or limitation of liability of officers or directors for breaches
of fiduciary duty as described in the previous sentence.
Section 145
of the Delaware General Corporation Law provides that a corporation has the power to indemnify a director, officer, employee or agent
of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including
attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by the person in connection
with an action, suit or proceeding to which he or she is party or is threatened to be made a party by reason of such position, if such
person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation,
and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case
of actions brought by or in the right of the corporation, no indemnification shall be made with respect to any claim, issue or matter
as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery
or other adjudicating court determines that, despite the adjudication of liability but in view of all of the circumstances of the case,
such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall
deem proper.
Our
certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any
threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an
action by or in the right of us) by reason of the fact that he or she is or was, or has agreed to become, our director or officer, or
is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity
with, another corporation, partnership, joint venture, trust or other enterprise (including any employee benefit plan) (all such persons
being referred to as an “Indemnitee”), or by reason of any action alleged to have been taken or omitted in such capacity,
against all expenses (including attorneys’ fees), liabilities, losses, judgments, fines, excise taxes and penalties arising under
the Employee Retirement Income Security Act of 1974, and amounts paid in settlement actually and reasonably incurred in connection with
such action, suit or proceeding and any appeal therefrom, if such Indemnitee acted in good faith and in a manner he or she reasonably
believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable
cause to believe his or her conduct was unlawful.
Our
certificate of incorporation also provides that we will indemnify any Indemnitee who was or is a party to any threatened, pending or
completed action or suit by or in the right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or
was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer,
partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise
(including any employee benefit plan), or by reason of any action alleged to have been taken or omitted in such capacity, against all
expenses (including attorneys’ fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred
in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a manner he
or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect
to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless a court determines that, despite
such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding
the foregoing, to the extent that any Indemnitee has been successful, on the merits or otherwise, he or she will be indemnified by us
against all expenses (including attorneys’ fees) actually and reasonably incurred by him or her or on his or her behalf in connection
therewith. If we don’t assume the defense, expenses must be advanced to an Indemnitee under certain circumstances.
We
maintain a general liability insurance policy which covers certain liabilities of our directors and officers arising out of claims based
on acts or omissions in their capacities as directors or officers.
Item
7. |
Exemption
from Registration Claimed. |
Not
applicable.
See
the Exhibit Index, which is incorporated herein by reference.
(a) The
Company hereby undertakes:
(1) To
file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i) To
include any prospectus required by Section 10(a)(3) of the Securities Act of 1933;
(ii) To
reflect in the prospectus any facts or events arising after the effective date of this Registration Statement (or the most recent post-effective
amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in this Registration
Statement;
(iii) To
include any material information with respect to the plan of distribution not previously disclosed in this Registration Statement or
any material change to such information in this Registration Statement;
Provided,
however, That
| (A) | Paragraphs
(a)(1)(i) and (a)(1)(ii) of this section do not apply if this Registration Statement
is on Form S-8, and the information required to be included in a post-effective amendment
by those paragraphs is contained in reports filed with or furnished to the Commission by
the Company pursuant to section 13 or section 15(d) of the Securities Exchange Act of
1934 (15 U.S.C. 78m or 78o(d)) that are incorporated by reference in this Registration Statement; |
(2) That,
for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to
be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be
deemed to be the initial bona fide offering thereof; and
(3) To
remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination
of the offering.
(b) The
undersigned Company hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of
the Company’s annual report pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934 (and, where
applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange
Act of 1934) that is incorporated by reference in this Registration Statement shall be deemed to be a new registration statement relating
to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide
offering thereof.
(h) Insofar
as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons
of the Company pursuant to the foregoing provisions, or otherwise, the Company has been advised that in the opinion of the Securities
and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the
event that a claim for indemnification against such liabilities (other than the payment by the Company of expenses incurred or paid by
a director, officer or controlling person of the Company in the successful defense of any action, suit or proceeding) is asserted by
such director, officer or controlling person in connection with the securities being registered, the Company will, unless in the opinion
of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether
such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue.
SIGNATURES
The Registrant. Pursuant
to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of
the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned,
thereunto duly authorized, in the City of Fort Lee, State of New Jersey, on this 9th day of August, 2023.
|
NUVECTIS
PHARMA, INC. |
|
|
|
By: |
/s/
Ron Bentsur |
|
|
Ron
Bentsur |
|
|
Chairman,
Chief Executive Officer, and President |
POWER
OF ATTORNEY
We,
the undersigned directors and/or executive officers of Nuvectis Pharma, Inc., hereby severally constitute and appoint Ron Bentsur,
acting singly, his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him and his name,
for him in any and all capacities, to sign this report and to file the same, with all exhibits thereto and other documents in connection
therewith, and to sign any or all amendments (including pre-effective and post-effective amendments) to this registration statement,
and to file the same, with all exhibits thereto and other documents in connection therewith, including any Registration Statement filed
pursuant to Rule 462(b) under the Securities Act of 1933, with the United States Securities and Exchange Commission, granting
unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary
to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming
all that said attorney-in-fact and agent or any of his substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant
to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities
and on the dates indicated.
Signature |
|
Title |
|
Date |
|
|
|
|
|
/s/ Ron Bentsur |
|
Chairman, Chief Executive Officer, and President |
|
August 9, 2023 |
Ron Bentsur |
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
/s/ Michael Carson |
|
Vice President of Finance Officer) |
|
August 9, 2023 |
Michael Carson |
|
(Principal Financial and Accounting officer) |
|
|
|
|
|
|
|
/s/ Kenneth Hoberman |
|
Director |
|
August 9, 2023 |
Kenneth Hoberman |
|
|
|
|
|
|
|
|
|
/s/ Matthew L. Kapan |
|
Director |
|
August 9, 2023 |
Matthew L. Kapan |
|
|
|
|
|
|
|
|
|
/s/ James F. Oliviero III |
|
Director |
|
August 9, 2023 |
James F. Oliviero III |
|
|
|
|
EXHIBIT INDEX
TO
REGISTRATION STATEMENT ON FORM S-8
Exhibit Number |
|
Description |
4.1 |
|
Second
Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc., filed as Exhibit 3.1 to the Form 8-K filed
on February 4, 2022 and incorporated herein by reference. |
|
|
|
4.2 |
|
Certificate
of Amendment to the Second Amended and Restated Certificate of Incorporation of Nuvectis Pharma, Inc., filed as Exhibit 3.3
to the Form 8-K filed on February 4, 2022 and incorporated herein by reference. |
|
|
|
4.3 |
|
Amended
and Restated Bylaws of Nuvectis Pharma, Inc., filed as Exhibit 3.2 to the Form 8-K filed on February 4, 2022 and
incorporated herein by reference. |
|
|
|
5.1 |
|
Opinion
of Alston & Bird LLP. |
|
|
|
23.1 |
|
Consent
of Kesselman & Kesselman. |
|
|
|
23.2 |
|
Consent
of Alston & Bird LLP (included in Exhibit 5.1). |
|
|
|
24.1 |
|
Power
of Attorney (included on signature page). |
|
|
|
99.1 |
|
Amended
and Restated Nuvectis Pharma, Inc. Global Equity Incentive Plan (2021) filed with the Definitive Proxy Statement on April 28,
2023, and incorporated herein by reference. |
|
|
|
107 |
|
Filing
fee table. |
Exhibit 5.1
90
Park Avenue
New York, NY 10016
212-210-9400
| Fax: 212-210-9444
Matthew
W. Mamak |
Direct
Dial: 212-210-1256 |
Email: matthew.mamak@alston.com |
August 9, 2023
Nuvectis
Pharma, Inc.
1
Bridge Plaza, Suite 275
Fort
Lee, NJ 07024
|
Re: |
Registration
Statement on Form S-8 |
Ladies
and Gentlemen:
We
are acting as counsel to Nuvectis Pharma, Inc., a Delaware corporation, (the “Company”) in connection with the registration
statement (the “Registration Statement”) on Form S-8 filed today by the Company with the Securities and Exchange Commission
(the “Commission”) to register under the Securities Act of 1933, as amended (the “Securities Act”),
1,000,000 shares of the Company’s common stock, $0.00001 par value per share (the “Shares”), which may be issued
by the Company upon the grant, exercise, settlement or purchase of awards pursuant to the Nuvectis Pharma, Inc. Global Incentive
Plan (2021) (the “Plan”). This opinion is furnished to you at your request in accordance with the requirements
of Item 8 of the Commission’s Form S-8 and Item 601(b)(5) of Regulation S-K promulgated under the Securities Act.
We
have examined the Second Amended and Restated Certificate of Incorporation of the Company, as amended, the Amended and Restated Bylaws
of the Company, records of proceedings of the Board of Directors of the Company (the “Board of Directors”), or committees
thereof, and records of proceedings of the stockholders, deemed by us to be relevant to this opinion letter and the Registration Statement.
We also have made such further legal and factual examinations and investigations as we deemed necessary for purposes of expressing the
opinion set forth herein.
As
to certain factual matters relevant to this opinion letter, we have relied conclusively upon originals or copies, certified or otherwise
identified to our satisfaction, of such records, agreements, documents and instruments, including certificates or comparable documents
of officers of the Company and of public officials, as we have deemed appropriate as a basis for the opinion hereinafter set forth. Except
to the extent expressly set forth herein, we have made no independent investigations with regard to matters of fact, and, accordingly,
we do not express any opinion as to matters that might have been disclosed by independent verification.
Our
opinion set forth below is limited to the General Corporation Law of the State of Delaware, applicable provisions of the Constitution
of the State of Delaware and reported judicial decisions interpreting such General Corporation Law and Constitution that, in our professional
judgment, are normally applicable to transactions of the type contemplated by the Plan, and we do not express any opinion herein concerning
any other laws.
Alston
& Bird LLP |
www.alston.com |
|
|
Atlanta
| Beijing | Brussels | Charlotte | Dallas | Fort Worth | London | Los Angeles | New York | Raleigh | San Francisco | Silicon Valley |
Washington, D.C.
August 9, 2023
Page 2
This
opinion letter is provided for use in connection with the transactions contemplated by the Registration Statement and may not be used,
circulated, quoted or otherwise relied upon for any other purpose without our express written consent. The only opinion rendered
by us consists of those matters set forth in the sixth paragraph hereof, and no opinion may be implied or inferred beyond the opinion
expressly stated. This opinion letter is rendered as of the date hereof and we make no undertaking and expressly disclaim any duty
to supplement or update the opinions rendered herein, if, after the date hereof, facts or circumstances come to our attention or changes
in the law occur which could affect such opinions. We note specifically that the Shares may be issued from time to time hereafter, and
our opinion is limited to the applicable laws, including the related rules and regulations, as in effect on the date hereof.
Based
on the foregoing, it is our opinion that the Shares to be issued under the Plan are duly authorized, and, when issued by the Company
in accordance with the terms of the Plan, will be legally issued, fully paid and non-assessable.
We
consent to the filing of this opinion letter as an exhibit to the Registration Statement. In giving such consent, we do not thereby
admit that we are within the category of persons whose consent is required under Section 7 of the Securities Act or the rules and
regulations of the Commission thereunder.
|
ALSTON
& BIRD LLP |
|
|
|
By: |
/s/
Matthew W. Mamak |
|
|
Matthew
W. Mamak |
|
|
Partner |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM
We hereby consent to the incorporation by reference in this Registration
Statement on Form S-8 of Nuvectis Pharma, Inc. of our report dated March 8, 2023, relating to the financial statements, which appears
in Nuvectis Pharma, Inc.'s Annual Report on Form 10-K for the year ended December 31, 2022.
Tel-Aviv, Israel |
/s/ Kesselman & Kesselman |
August 9, 2023 |
Certified Public Accountants (Isr.) |
|
A member firm of PricewaterhouseCoopers International Limited |
Exhibit 107
Calculation of Filing Fee Tables
Form S-8
(Form Type)
NUVECTIS PHARMA, INC.
(Exact Name of Registrant as Specified in its Charter)
Table 1: Newly Registered Securities
Security
Type |
Security Class Title |
Fee
Calculation
Rule |
Amount
Registered
(1) |
Proposed Maximum Offering
Price Per
Share |
Maximum Aggregate Offering
Price |
Fee Rate |
Amount of Registration
Fee |
Equity |
Common Stock, $0.00001 par value |
Other (457(c) and 457(h)) |
1,000,000 (1) |
$14.35
(2) |
$14,350,000 (2) |
0.00011020 |
$1,581.37 |
Total Offering Amounts |
|
$14,350,000 |
|
$1,581.37 |
Total Fee Offsets(3) |
|
|
|
— |
Net Fee Due |
|
|
|
$1,581.37 |
| (1) | Represents
shares that may be issued under the Nuvectis Pharma, Inc. Amended and Restated Global
Incentive Plan (2021) (the “Plan”), including additional shares that may become
issuable in accordance with the adjustment and anti-dilution provisions of the Plan. |
| (2) | Determined
pursuant to Rule 457(c) and 457(h) under the Securities Act of 1933, as amended (the “Securities Act”), solely
for the purpose of calculating the registration fee, based on the average of the high and low prices of the Company’s common stock
(“Common Stock”) on the Nasdaq Capital Market on August 7, 2023. |
| (3) | The
Registrant does not have any fee offsets. |
Nuvectis Pharma (NASDAQ:NVCT)
Historical Stock Chart
From May 2024 to Jun 2024
Nuvectis Pharma (NASDAQ:NVCT)
Historical Stock Chart
From Jun 2023 to Jun 2024